치료용 혈장 교환 시장 : 기술, 적응증, 제품, 최종사용자별 - 세계 예측(2025-2030년)

The Therapeutic Plasma Exchange Market was valued at USD 792.04 million in 2023, expected to reach USD 878.53 million in 2024, and is projected to grow at a CAGR of 9.81%, to USD 1,525.84 million by 2030.

Therapeutic Plasma Exchange (TPE) is a vital medical procedure involving the removal, treatment, and reinfusion of plasma to manage various health conditions such as autoimmune diseases, neurological disorders, and hematological disorders. Its necessity arises from the procedure's ability to remove pathogenic substances from the blood, which is crucial for patients unresponsive to conventional treatments. TPE finds applications in treating diseases like Guillain-Barre Syndrome, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, and Atypical Hemolytic Uremic Syndrome, with hospitals and specialty clinics being primary end-users. The market for TPE is growing, driven by increasing incidences of autoimmune diseases, advancements in healthcare infrastructure, and a rising aging population. Technological advancements like the development of more efficient and safer apheresis devices and increasing awareness of TPE's therapeutic benefits are key growth drivers. However, the market faces challenges such as high procedural costs, limited reimbursement policies, and the need for highly skilled healthcare professionals. Additionally, the scarcity of skilled technicians and limited accessibility in developing regions hinder growth. Despite these challenges, opportunities lie in expanding applications for emerging autoimmune conditions and innovating cost-effective and user-friendly apheresis devices. Investment in research and development, along with strategic collaborations and partnerships, could accelerate growth and widen the application scope. Companies can leverage data analytics to optimize procedures and enhance patient outcomes. Furthermore, telemedicine can support remote monitoring and post-treatment care, adding value to service delivery. However, regulations concerning medical device approval and the ethical implications of plasma procurement highlight areas requiring careful navigation. To stay competitive, companies should focus on personalized medicine approaches, integrating advanced technology to offer tailored therapeutic plasma exchange solutions that align with patient-specific needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic Plasma Exchange Market

The Therapeutic Plasma Exchange Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Need of Therapeutic Plasma Exchange due to Rise in Prevalence of Autoimmune and Cardiac Diseases
  • Technical Advancement in Apheresis Technologies
• Market Restraints
  • Cost Associated with the Devices and Therapeutic Plasma Exchange Procedures
• Market Opportunities
  • Advancement in Therapeutic Plasma Exchange Technology and its Immunomodulatory Effect in Neuromuscular Diseases
  • Surge in Demand for Therapeutic Plasma Exchange (TPE) in Pediatric Intensive Care
• Market Challenges
  • Complications Associated with the Apheresis Procedure in TPE

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic Plasma Exchange Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic Plasma Exchange Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic Plasma Exchange Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic Plasma Exchange Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic Plasma Exchange Market

A detailed market share analysis in the Therapeutic Plasma Exchange Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic Plasma Exchange Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic Plasma Exchange Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Plasma Exchange Market, highlighting leading vendors and their innovative profiles. These include Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, CSL Behring, Kedrion Biopharma Inc., Medica S.P.A., Elastrin Therapeutics, Inc., B. Braun Melsungen AG, Pall Corporation, Medicap Clinic GmbH, Infomed SA, Terumo BCT, Inc., Qingdao Haier Biomedical Co., Ltd, Mallinckrodt PLC, Fresenius Medical Care AG & Co. KGaA, Kaneka Corporation, MEISE Medizintechnik GmbH, Nikkiso Co., Ltd., Grifols, S.A., Sb-Kawasumi Laboratories, Inc., Charles River Laboratories International, Inc., Cerus Corporation, Plasma Technologies, LLC, Miltenyi Biotec, Bio Products Laboratory Ltd., and Baxter International Inc..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Plasma Exchange Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Centrifugation and Membrane Separation.
• Based on Indication, market is studied across Hematologic Disorders, Metabolic Disorders, Neurological Disorders, and Renal Disorders. The Hematologic Disorders is further studied across Atypical Hemolytic Uremic Syndrome, Hyperviscosity Syndrome, Severe/Symptomatic Cryoglobulinemia, and Thrombotic Thrombocytopenic Purpura. The Neurological Disorders is further studied across Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, and PANDAS. The Renal Disorders is further studied across Antibody-mediated Renal Transplant Rejection, Goodpasture Syndrome, and Wegener's Granulomatosis.
• Based on Product, market is studied across Consumables and Devices.
• Based on End-user, market is studied across Blood Collection Centers & Blood Component Providers and Hospitals & Transfusion Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Need of Therapeutic Plasma Exchange due to Rise in Prevalence of Autoimmune and Cardiac Diseases
    • 5.1.1.2. Technical Advancement in Apheresis Technologies
  • 5.1.2. Restraints
    • 5.1.2.1. Cost Associated with the Devices and Therapeutic Plasma Exchange Procedures
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancement in Therapeutic Plasma Exchange Technology and its Immunomodulatory Effect in Neuromuscular Diseases
    • 5.1.3.2. Surge in Demand for Therapeutic Plasma Exchange (TPE) in Pediatric Intensive Care
  • 5.1.4. Challenges
    • 5.1.4.1. Complications Associated with the Apheresis Procedure in TPE
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Membrane separation are preferred selection while therapeutic plasma exchange
  • 5.2.2. Indication: Extensive usage of therapeutic plasma exchange for life threatening hematologic disorders
  • 5.2.3. Product: Technological advancement in consumables needs should to be compatible with their plasma exchange devices and systems
  • 5.2.4. End-user: Blood collection centers & blood component providers are commanding larger user base and support for large scale operative treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Therapeutic Plasma Exchange Market, by Technology

• 6.1. Introduction
• 6.2. Centrifugation
• 6.3. Membrane Separation

7. Therapeutic Plasma Exchange Market, by Indication

• 7.1. Introduction
• 7.2. Hematologic Disorders
  • 7.2.1. Atypical Hemolytic Uremic Syndrome
  • 7.2.2. Hyperviscosity Syndrome
  • 7.2.3. Severe/Symptomatic Cryoglobulinemia
  • 7.2.4. Thrombotic Thrombocytopenic Purpura
• 7.3. Metabolic Disorders
• 7.4. Neurological Disorders
  • 7.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
  • 7.4.2. Guillain-Barre Syndrome
  • 7.4.3. Multiple Sclerosis
  • 7.4.4. Myasthenia Gravis
  • 7.4.5. PANDAS
• 7.5. Renal Disorders
  • 7.5.1. Antibody-mediated Renal Transplant Rejection
  • 7.5.2. Goodpasture Syndrome
  • 7.5.3. Wegener's Granulomatosis

8. Therapeutic Plasma Exchange Market, by Product

• 8.1. Introduction
• 8.2. Consumables
• 8.3. Devices

9. Therapeutic Plasma Exchange Market, by End-user

• 9.1. Introduction
• 9.2. Blood Collection Centers & Blood Component Providers
• 9.3. Hospitals & Transfusion Centers

10. Americas Therapeutic Plasma Exchange Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Therapeutic Plasma Exchange Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Plasma Exchange Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Dr. Savage Introduces Plasma Exchange for 2024 Weight Loss
  • 13.3.2. HealthyLongevity.clinic recently partnered with Dr. Dobri Kiprov
  • 13.3.3. MaxWell Clinic offers Therapeutic Plasma Exchange (TPE) as a Treatment Option for Dementia, Alzheimer's, Memory Los, and Autoimmune Disease

Companies Mentioned

• 1. Asahi Kasei Medical Co., Ltd.
• 2. Haemonetics Corporation
• 3. CSL Behring
• 4. Kedrion Biopharma Inc.
• 5. Medica S.P.A.
• 6. Elastrin Therapeutics, Inc.
• 7. B. Braun Melsungen AG
• 8. Pall Corporation
• 9. Medicap Clinic GmbH
• 10. Infomed SA
• 11. Terumo BCT, Inc.
• 12. Qingdao Haier Biomedical Co., Ltd
• 13. Mallinckrodt PLC
• 14. Fresenius Medical Care AG & Co. KGaA
• 15. Kaneka Corporation
• 16. MEISE Medizintechnik GmbH
• 17. Nikkiso Co., Ltd.
• 18. Grifols, S.A.
• 19. Sb-Kawasumi Laboratories, Inc.
• 20. Charles River Laboratories International, Inc.
• 21. Cerus Corporation
• 22. Plasma Technologies, LLC
• 23. Miltenyi Biotec
• 24. Bio Products Laboratory Ltd.
• 25. Baxter International Inc.